Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 7, 2006; 12(29): 4716-4720
Published online Aug 7, 2006. doi: 10.3748/wjg.v12.i29.4716
Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma
Aldo Spadaro, Antonino Ajello, Carmelo Luigiano, Carmela Morace, Maria Letizia Resta, Grazia Berlinghieri, Salvatore Campo, Claudio Scisca, Angela Alibrandi, Graziella D’arrigo, Nunziata Alessi, Oscar Ferraù, Maria Antonietta Freni
Aldo Spadaro, Antonino Ajello, Carmelo Luigiano, Carmela Morace, Maria Letizia Resta, Grazia Berlinghieri, Salvatore Campo, Claudio Scisca, Angela Alibrandi, Graziella D’arrigo, Nunziata Alessi, Oscar Ferraù, Maria Antonietta Freni, Dipartimento Clinico Sperimentale di Medicina e Farmacologia, Clinica Medica, Pad. C, AOU, Via Consolare Valeria No. 1, Messina 98125, Italy
Correspondence to: Dr. Aldo Spadaro, Dipartimento Clinico Sperimentale di Medicina e Farmacologia, Clinica Medica, Pad. C, AOU, Via Consolare Valeria No. 1, Messina 98125, Italy. aldo.spadaro@unime.it
Telephone: +39-90-2212333 Fax: +39-90-693917
Received: February 6, 2006
Revised: February 28, 2006
Accepted: February 28, 2006
Published online: August 7, 2006
Abstract

AIM: The utility of serum alpha-fetoprotein (α-FP) in the detection of hepatocellular carcinoma (HCC) is questionable. Very high circulating levels of nociceptin/orphanin FQ (N/OFQ), a ligand for a novel opioid receptor, have recently been reported in HCC. The aim of this study was to assess the role of plasma N/OFQ in the diagnosis of HCC arising in patients with liver cirrhosis.

METHODS: Plasma N/OFQ levels were measured by ELISA in 58 patients (28 HCC and 30 liver cirrhosis) and in 25 healthy controls. The values were correlated with clinical and laboratory features including α-FP. Spearman index, biserial correlation coefficient, non parametric combination (NPC) test and discriminant stepwise analysis were used for statistical evaluation of data.

RESULTS: The upper normal limit of nociceptin was 122 pg/mL. Plasma levels above this cut-off were found in 21.4% of patients with HCC, in 23.3% of those with cirrhosis and in 8% of healthy subjects. α-FP serum levels > 200 ng/mL were found in 46.4% of the patients with HCC and in none of those with cirrhosis. No correlation was found between N/OFQ levels and any of the clinical and laboratory features, including α-FP. By NPC test, HCC and cirrhotic patients were different with regard to α-FP (P = 0.000) but not in terms of nociceptin (P = 0.595). By point biserial correlation, HCC presence was positively correlated with α-FP (rpb = 0.52, P = 0.000) but not with N/OFQ (rpb = 0.16, P = 0.157). In a discriminant analysis, α-FP was significant in the Wilks test (Y = -0.709 + 0.03 α-FP) and properly classified 81% of all patients and 61% of HCC. N/OFQ had lower sensitivity, specificity and predictive values than α-FP.

CONCLUSION: Nociceptin is increased in patients with chronic liver disease, independently of the presence of HCC, although the underlying mechanism has yet to be clarified. We conclude it is not a useful marker for HCC.

Keywords: Hepatocellular carcinoma; Nociceptin/orphanin FQ; Liver cirrhosis; Alpha-fetoprotein